Global food and nutritional ingredients supplier DSM continues its €100 million investment in R&D with the opening of a new biotechnology facility near its Delft HQ for food.
Sales slipped 6% and net profits 11% in Q2 for DSM’s human and animal nutrition arm as adverse currency movements, a slow US vitamins and omega-3 food supplements market and the Asian botulism infant formula scare affected earnings.
Royal DSM paid tribute to its nutrition division which held steady as its sales and profits dipped for the second quarter and first half of the financial year, as recessed global economies took their toll on bottom lines.
Nutrition and polymers were the stand-out divisions for Royal DSM in 2011, a year that saw operating profits rise 15% from €752m to €866m, as the newly life science-oriented ingredients giant singled out Martek buy-out success and committed to ongoing...
